Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL234461 | 0.72 | ALDH1A1 (0.58) | ALDH1A1HSD17B10TSHRMAPK1TP53 | |
| SCHEMBL1408568 | 0.69 | ALDH1A1 (0.44) | ALDH1A1HSD17B10TSHRMAPK1TP53 | |
| SCHEMBL9073535 | 0.69 | ALDH1A1 (0.44) | ALDH1A1HSD17B10TSHRMAPK1TP53 | |
| SCHEMBL11447692 | 0.68 | ALDH1A1 (0.39) | ALDH1A1HSD17B10TSHRMAPK1TP53 | |
| SCHEMBL27660168 | 0.67 | ALDH1A1 (0.52) | ALDH1A1HSD17B10TSHRMAPK1TP53 | |
| SCHEMBL107699 | 0.66 | — | — | |
| SCHEMBL12263887 | 0.65 | MGLL (0.68) | ALDH1A1MAPK1TDP1HSP90AA1LMNA | |
| SCHEMBL24385153 | 0.64 | ALDH1A1 (0.50) | ALDH1A1HSD17B10TSHRMAPK1TP53 | |
| SCHEMBL10887099 | 0.64 | ALDH1A1 (0.50) | ALDH1A1HSD17B10TSHRMAPK1TP53 | |
| SCHEMBL27251960 | 0.64 | ALDH1A1 (0.50) | ALDH1A1HSD17B10TSHRMAPK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145591-A1 | INHIBITORS OF ADVANCED GLYCATION END PRODUCTS | PRAETEGO INC | 2025-05-08 | — | — | US | disclosed |
| US-20250101000-A1 | INHIBITORS OF ADVANCED GLYCATION END PRODUCTS | PRAETEGO INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-12139472-B2 | Inhibitors of advanced glycation end products | PRAETEGO INC (US) | 2024-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145591-A1 | INHIBITORS OF ADVANCED GLYCATION END PRODUCTS | AGER, GLA, GPR119 | ALDH1A1 470/4885HSD17B10 3367/4885TSHR 1674/4885 |
| US-20250101000-A1 | INHIBITORS OF ADVANCED GLYCATION END PRODUCTS | AGER, GLA, GPR119 | ALDH1A1 470/4885HSD17B10 3367/4885TSHR 1674/4885 |
| US-12139472-B2 | Inhibitors of advanced glycation end products | AGER, GLA, FN3K | ALDH1A1 439/4885HSD17B10 3180/4885TSHR 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.